IL-6, markedly elevated in cancer patients and with levels correlating with disease stage and prognosis [39,40], exerts profound prothrombotic effects by inducing hepatic synthesis of fibrinogen and factor VIII, upregulating TF on monocytes, while suppressing anticoagulant protein S and antithrombin [38,41]. Here, IL6 is linked to cancer.